Altimmune Inc (ALT) Business News Dec. 19, 2025, 11:30 UTC Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial Full text
There are no comments here yet...